Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
- Korean Study Links Weight-Loss Drugs to Higher Depression and Suicidal Thoughts
- 1866 storm rescue recreation part of festivities
- 6 Hidden Gems in Brazil for Retirees Seeking a Serene, Affordable Lifestyle
- ‘Mothers get lost in the shuffle’: The Clancy trial highlights gaps in postpartum mental health care
- Analytic Philosophy Is the Ideology of the Status Quo
- J-16 fighters fly 3,700 miles for China
- Frontier Health launches campaign to support domestic violence shelter
- No new H1N1 strain in India, existing vaccines sufficient, says ICMR
Browsing: Ozempic
The arrival of GLP-1 drugs such as semaglutide and tirzepatide, popularly known as Ozempic and Mounjaro, has transformed the treatment of obesity and type 2 diabetes, while also reducing the risk of heart disease and kidney complications
Brazil’s national drug regulator approved five semaglutide injection pens simultaneously on Wednesday — the largest single-day batch of GLP-1 receptor agonist clearances any health agency has issued in the country’s history — yet none of the drugs can reach a pharmacy shelf until Brazil’s drug pricing chamber sets a price cap, a separate regulatory step…
Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for type II diabetes [T2D]) and Wegovy (for obesity)
Weight loss jabs such as Wegovy and Mounjaro have boomed in popularity, and so have reports of myriad side-effects. This week researchers have suggested GLP-1 medications could be associated with hair loss
People taking semaglutide for weight loss maintained a significantly lower calorie intake after 60 weeks on the medication, according to a new study
Research into GLP-1 medications is not always robust but complaints such as digestive problems are well known
GLP-1 medications have been shown to improve health and offer strong value for their price, yet many insurance plans continue to restrict access. Researchers at the University of Mississippi are investigating the financial and practical reasons behind those limits, along with the consequences for patients
GLP-1 medications commonly used to manage type 2 diabetes and obesity may be associated with a modest increase in hair loss, according to a study published by The BMJ on July 22, 2026
The increased use of weight-loss drugs has created a big opportunity for aesthetics company Galderma, its CEO told CNBC on Thursday
1 medications like semaglutide, the active ingredient in Ozempic and Wegovy, have become some of the most popular drugs in the world. Its popularity is extending to teenagers and young adults, too, research out this week shows

